Pharmaceutical company Shield Therapeutics (LON:STX) released a stock market announcement on Tuesday outlining the appointment of a new Chairman. Indeed, James Karis has been appointed as the new non-executive Chairman of Shield Therapeutics.

James Karis has been on Shield Therapeutics’ board of directors for almost three years. He brings to the pharmaceutical company over 35 years of experience in the pharmaceutical, healthcare services, technology and medical device industries.

The former Chairman, Andrew Heath, stood down from his position at the company’s AGM.

James Karis commented on his appointment as Chairman of Shield Therapeutics:

“It is exciting to take on an expanded role as Chairman of Shield Therapeutics during a time when the Company has several important milestones on the horizon.  I look forward to working with the rest of the Board and management team in continuing our efforts to provide a unique therapy benefiting patients around the world while making Shield a success for its shareholders.”

Shield Therapeutics is a commercial stage, pharmaceutical company with an initial focus on iron deficiency.

CEO of the company, Carl Sterritt, also commented on the announcement:

“I am very pleased to see James appointed as our Chair.  The understanding of the business and the opportunity for Feraccru that he has developed over the last three years of Shield Therapeutics, combined with his extensive leadership experience and multiple exposures to licensing, mergers and acquisitions, not least in the USA, will, I am sure, prove to be of significant value to Shield’s shareholders.  I look forward to working closely with and benefitting from his counsel as we look to execute on our strategy to crystallise the significant value that exists in our excellent product portfolio.”

In December 2018, the company announced that it would expand its iron deficiency treatment for children, introducing child trials in 2019.

The company’s product Feraccru is undergoing a process of US approval. A decision is expected to be made by the 27th July.